VeriSIM Life

The AI engine Fit Assessment

Beta

VeriSIM Life effectively leverages machine learning to enhance drug development, discover patterns in drug interactions, and expand therapeutic options, including drug repurposing.

Blurb

VeriSIM Life is a computational bioplatform that predicts the clinical outcomes of new drugs before clinical trials.

HQ Location

San Francisco (United States)

Founded

2017

Employees

11 - 50

Total funding raised

$21.66M

Funding Status

Series A, $15.00M, January 13, 2022
Subspaces
  • Drug Repurposing

VeriSIM Life is building AI enabled biosimulation models.

VeriSIM will tackle one of the biggest obstacles of drug development: animal testing for drug development. Animal testing is slow, ethically questionable, and doesn't act as much of a filter: 92% of all drug candidates that pass this preclinical testing never make it to market.



VeriSIM's solution is to create disease-specific biosimulation models, which allow researchers at pharma companies to model in software how a drug will interact in animals. This will allow researchers to test 1000x more potential candidates in the same unit of time, ensuring that drugs that do make it to (human) clinical trials are far more likely to work, and therefore saving millions in annual costs.